Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO ®, Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA ®, Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ ®, Genentech), …